PharmaVoice 9 mar 2026 The first KRAS drugs have been sluggish on the market. Will the next generation fare better?
PharmaVoice 3 mar 2026 J&J’s blockbuster Spravato is setting the stage for managing psychedelics’ risks
PharmaVoice 19 feb 2026 Will vaccine regulatory uncertainty chill innovation? Pharma execs sound off.